Please enable JavaScript to continue using this application.

Compare $CHRS vs $VYGR | Chartloom

Compare

$CHRS vs $VYGR

Coherus Oncology Inc · Voyager Therapeutics Inc

CHRS

Coherus Oncology Inc

VYGR

Voyager Therapeutics Inc

Compare $CHRS vs $VYGR

Comparing Coherus Oncology Inc and Voyager Therapeutics Inc

CHRSCoherus Oncology Inc

VYGRVoyager Therapeutics Inc

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

VYGRVoyager Therapeutics Inc

Market cap

$148M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.33x

Rev growth (TTM)

-19.1%

YTD performance

-39.2%

52W performance

-53.6%

FCF yield

-82.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

VYGR

Detailed metrics comparison

CHRS

Coherus Oncology Inc

VYGR

Voyager Therapeutics Inc

Market Cap

CHRS$165M

VYGR$148M

Enterprise Value

CHRS$134M

VYGR$112M

Price

CHRS$1.07

VYGR$2.45

P/E Ratio

CHRSN/A

VYGRN/A

P/S Ratio

CHRS3.24x

VYGR4.30x

EV/Sales

CHRS2.63x

VYGR3.26x

EV/EBITDA

CHRS2.57x

VYGR8.61x

P/B Ratio

CHRS2.95x

VYGR1.01x

P/FCF Ratio

CHRSN/A

VYGRN/A

EV/FCF

CHRS-0.72x

VYGR-0.92x

PEG Ratio

CHRSN/A

VYGRN/A

Forward P/E (NTM)

CHRSN/A

VYGRN/A

Forward P/S (NTM)

CHRS2.04x

VYGR5.33x

Revenue (TTM)

CHRS$51M

VYGR$34M

Revenue Growth (YoY)

CHRS-64.3%

VYGR-19.1%

Forward Rev Growth

CHRS67.8%

VYGR129.7%

Gross Margin (TTM)

CHRS68.9%

VYGR0.0%

Operating Margin (TTM)

CHRS0.0%

VYGR0.0%

EBITDA Margin (TTM)

CHRS-288.0%

VYGR-329.0%

Net Margin (TTM)

CHRS-259.4%

VYGR-312.6%

FCF Margin (TTM)

CHRS-365.2%

VYGR-352.4%

Net Income (TTM)

CHRS$-132M

VYGR$-108M

FCF (TTM)

CHRS$-186M

VYGR$-121M

EPS (TTM)

CHRS-$0.85

VYGR-$1.78

ROE (TTM)

CHRS-18336.0%

VYGR-5792.0%

ROA (TTM)

CHRS-4290.0%

VYGR-4500.0%

ROIC (TTM)

CHRS-10716.0%

VYGR-5792.0%

Cash

CHRS$83M

VYGR$36M

Debt

CHRS$52M

VYGR$0

Net Cash/Debt

CHRS$31M

VYGR$36M

Current Ratio (TTM)

CHRS1.77x

VYGR7.51x

Quick Ratio (TTM)

CHRS1.58x

VYGR7.16x

Debt/Equity (TTM)

CHRS0.85x

VYGR0.00x

Debt/Assets (TTM)

CHRS0.0%

VYGR0.0%

Interest Coverage (TTM)

CHRSN/A

VYGRN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

VYGR0.00x

Beta

CHRS0.99

VYGR1.11

52W Performance

CHRS-39.2%

VYGR-53.6%

YTD Performance

CHRS-21.9%

VYGR-39.2%

% from 52W High

CHRS-59.1%

VYGR-55.9%

% from 52W Low

CHRS9.9%

VYGR5.2%

Asset Turnover (TTM)

CHRS0.17x

VYGR0.14x

FCF Yield (TTM)

CHRS-112.7%

VYGR-82.0%

Earnings Yield (TTM)

CHRS-80.1%

VYGR-72.8%

Dividend Yield (TTM)

CHRSN/A

VYGRN/A

Rule of 40

CHRS-429.5

VYGR-371.4

EV/GP/RG

CHRS0.05

VYGRN/A

Ticker research

View CHRS research View VYGR research

Metric	CHRS Coherus Oncology Inc	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$165M	$148M
Enterprise Value	$134M	$112M
Price	$1.07	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	4.30x
EV/Sales	2.63x	3.26x
EV/EBITDA	2.57x	8.61x
P/B Ratio	2.95x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	5.33x
Revenue & Growth
Revenue (TTM)	$51M	$34M
Revenue Growth (YoY)	-64.3%	-19.1%
Forward Rev Growth	67.8%	129.7%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	-329.0%
Net Margin (TTM)	-259.4%	-312.6%
FCF Margin (TTM)	-365.2%	-352.4%
Net Income (TTM)	$-132M	$-108M
FCF (TTM)	$-186M	$-121M
EPS (TTM)	-$0.85	-$1.78
ROE (TTM)	-18336.0%	-5792.0%
ROA (TTM)	-4290.0%	-4500.0%
ROIC (TTM)	-10716.0%	-5792.0%
Financial Health
Cash	$83M	$36M
Debt	$52M	$0
Net Cash/Debt	$31M	$36M
Current Ratio (TTM)	1.77x	7.51x
Quick Ratio (TTM)	1.58x	7.16x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.11
52W Performance	-39.2%	-53.6%
YTD Performance	-21.9%	-39.2%
% from 52W High	-59.1%	-55.9%
% from 52W Low	9.9%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.14x
FCF Yield (TTM)	-112.7%	-82.0%
Earnings Yield (TTM)	-80.1%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	-371.4
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View VYGR research

Valuation

P/S Ratio

CHRS

3.24x

VYGR

4.30x

EV/FCF

VYGR

-0.92x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

VYGR

-19.1%

CHRS

-64.3%

Forward Revenue Growth

VYGR

129.7%

CHRS

67.8%

Profitability & performance

Gross Margin

CHRS

68.9%

VYGR

0.0%

ROE

VYGR

-5792.0%

CHRS

-18336.0%

FCF Yield %

VYGR

-82.0%

CHRS

-112.7%

52-Week Performance

CHRS

-39.2%

VYGR

-53.6%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

VYGR

Voyager Therapeutics Inc

Market Cap

CHRS$165M

VYGR$148M

Enterprise Value

CHRS$134M

VYGR$112M

Price

CHRS$1.07

VYGR$2.45

P/E Ratio

CHRSN/A

VYGRN/A

P/S Ratio

CHRS3.24x

VYGR4.30x

EV/Sales

CHRS2.63x

VYGR3.26x

EV/EBITDA

CHRS2.57x

VYGR8.61x

P/B Ratio

CHRS2.95x

VYGR1.01x

P/FCF Ratio

CHRSN/A

VYGRN/A

EV/FCF

CHRS-0.72x

VYGR-0.92x

PEG Ratio

CHRSN/A

VYGRN/A

Forward P/E (NTM)

CHRSN/A

VYGRN/A

Forward P/S (NTM)

CHRS2.04x

VYGR5.33x

Revenue (TTM)

CHRS$51M

VYGR$34M

Revenue Growth (YoY)

CHRS-64.3%

VYGR-19.1%

Forward Rev Growth

CHRS67.8%

VYGR129.7%

Gross Margin (TTM)

CHRS68.9%

VYGR0.0%

Operating Margin (TTM)

CHRS0.0%

VYGR0.0%

EBITDA Margin (TTM)

CHRS-288.0%

VYGR-329.0%

Net Margin (TTM)

CHRS-259.4%

VYGR-312.6%

FCF Margin (TTM)

CHRS-365.2%

VYGR-352.4%

Net Income (TTM)

CHRS$-132M

VYGR$-108M

FCF (TTM)

CHRS$-186M

VYGR$-121M

EPS (TTM)

CHRS-$0.85

VYGR-$1.78

ROE (TTM)

CHRS-18336.0%

VYGR-5792.0%

ROA (TTM)

CHRS-4290.0%

VYGR-4500.0%

ROIC (TTM)

CHRS-10716.0%

VYGR-5792.0%

Cash

CHRS$83M

VYGR$36M

Debt

CHRS$52M

VYGR$0

Net Cash/Debt

CHRS$31M

VYGR$36M

Current Ratio (TTM)

CHRS1.77x

VYGR7.51x

Quick Ratio (TTM)

CHRS1.58x

VYGR7.16x

Debt/Equity (TTM)

CHRS0.85x

VYGR0.00x

Debt/Assets (TTM)

CHRS0.0%

VYGR0.0%

Interest Coverage (TTM)

CHRSN/A

VYGRN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

VYGR0.00x

Beta

CHRS0.99

VYGR1.11

52W Performance

CHRS-39.2%

VYGR-53.6%

YTD Performance

CHRS-21.9%

VYGR-39.2%

% from 52W High

CHRS-59.1%

VYGR-55.9%

% from 52W Low

CHRS9.9%

VYGR5.2%

Asset Turnover (TTM)

CHRS0.17x

VYGR0.14x

FCF Yield (TTM)

CHRS-112.7%

VYGR-82.0%

Earnings Yield (TTM)

CHRS-80.1%

VYGR-72.8%

Dividend Yield (TTM)

CHRSN/A

VYGRN/A

Rule of 40

CHRS-429.5

VYGR-371.4

EV/GP/RG

CHRS0.05

VYGRN/A

Ticker research

View CHRS research View VYGR research

Metric	CHRS Coherus Oncology Inc	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$165M	$148M
Enterprise Value	$134M	$112M
Price	$1.07	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	4.30x
EV/Sales	2.63x	3.26x
EV/EBITDA	2.57x	8.61x
P/B Ratio	2.95x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	5.33x
Revenue & Growth
Revenue (TTM)	$51M	$34M
Revenue Growth (YoY)	-64.3%	-19.1%
Forward Rev Growth	67.8%	129.7%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	-329.0%
Net Margin (TTM)	-259.4%	-312.6%
FCF Margin (TTM)	-365.2%	-352.4%
Net Income (TTM)	$-132M	$-108M
FCF (TTM)	$-186M	$-121M
EPS (TTM)	-$0.85	-$1.78
ROE (TTM)	-18336.0%	-5792.0%
ROA (TTM)	-4290.0%	-4500.0%
ROIC (TTM)	-10716.0%	-5792.0%
Financial Health
Cash	$83M	$36M
Debt	$52M	$0
Net Cash/Debt	$31M	$36M
Current Ratio (TTM)	1.77x	7.51x
Quick Ratio (TTM)	1.58x	7.16x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.11
52W Performance	-39.2%	-53.6%
YTD Performance	-21.9%	-39.2%
% from 52W High	-59.1%	-55.9%
% from 52W Low	9.9%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.14x
FCF Yield (TTM)	-112.7%	-82.0%
Earnings Yield (TTM)	-80.1%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	-371.4
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View VYGR research